Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

January Court Date Set for Abbott, Alere Merger

Executive Summary

A hearing in Alere’s court case to force Abbott to complete the merger has been set for Jan. 27. The hearing will only be held if the companies can’t complete the merger by that date. Delaware Chancery Court has also adopted Abbott’s proposed schedule for merger activities.

You may also be interested in...



Abbott Steps Up Effort To Abandon Alere Deal

Abbott has asked a Delaware court to cancel its agreement to buy Alere for $5.8bn based on a series of financial and regulatory missteps by Alere. Alere, which earlier sued to force the merger to go through, plans to fight the suit.

Earnings Winners & Losers: QGEN, WMGI, ALR, SN, and LIVN

Diagnostics, orthopedics, and cardiovascular device companies are among those that wait until November to report their results for the quarter that ended at the end of September. Medtech Insight’s Earnings Winners & Losers highlights some of the companies that had news to celebrate, and a few that were disappointed with the quarter.

Abbott, Alere Agree To Mediation For Troubled Merger

Abbott announced plans to purchase Alere in January, but the merger has so far been delayed by, Alere alleges, Abbott's foot-dragging. Abbott, meanwhile, points to federal investigations that have delayed Alere’s financial filings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT103921

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel